Editor's Note: In the field of urologic oncology, systemic treatment for advanced renal cell carcinoma (RCC) has fully entered the era of targeted therapy combined with immunotherapy (targeted therapy–immunotherapy combinations). However, how to make precise, individualized treatment decisions for patients across different risk groups, and how to select the optimal subsequent-line regimen after treatment failure, remain major clinical challenges. At the recent 2026 CACAGU Academic Conference, Professor Shuiping Yin and Professor Zhaozhao Liang from the Department of Urology, The First Affiliated Hospital of Anhui Medical University, delivered an in-depth presentation entitled Individualized Treatment and Latest Research Advances in Advanced Renal Tumors. This article highlights the key points of their presentation and systematically reviews individualized first-line treatment decisions, investigations of triplet combinations, advances in second-line treatment, and surgical management of complex tumor thrombi.

Individualized First-Line Treatment: A Precision Decision-Making Pathway Based on IMDC Risk Stratification

For first-line systemic treatment of advanced clear cell renal cell carcinoma (ccRCC), clinical decision-making currently relies heavily on the prognostic risk stratification model developed by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). According to the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Renal Cancer, tyrosine kinase inhibitor (TKI) monotherapy, such as sunitinib or pazopanib, both of which carry a Category 1A recommendation, is preferentially recommended for patients at low risk. For patients at intermediate or high risk, targeted therapy–immunotherapy combinations or dual-immunotherapy regimens are preferred.

Long-term follow-up data from several pivotal Phase III clinical trials, including KEYNOTE-426, CheckMate 9ER, and CLEAR, have further validated the need for this risk-stratified approach. In KEYNOTE-426, although axitinib plus pembrolizumab demonstrated an overall survival benefit in the overall population (median OS [mOS], 47.2 months vs. 40.8 months), it did not achieve a significant survival benefit over sunitinib in the IMDC favorable-risk subgroup (HR = 1.10, 95% CI: 0.79–1.54). Similar findings were observed in CheckMate 9ER (nivolumab plus cabozantinib) and CLEAR (lenvatinib plus pembrolizumab). Data indicate that, although targeted therapy–immunotherapy combinations offer a PFS advantage in low-risk patients, the OS hazard ratios are often close to 1.0 (e.g., OS HR = 0.94 in the low-risk subgroup of CLEAR and 1.08 in CheckMate 9ER), suggesting that the survival benefit of these combinations is relatively limited in this population.

The Chinese Expert Consensus on Systemic Treatment of Advanced Clear Cell Renal Cell Carcinoma (2024 Edition) explicitly states that first-line treatment should be selected through comprehensive consideration of prognostic risk, tumor burden, metastatic characteristics, and molecular subtype. For low-risk patients with a relatively small burden of distant metastases, a small primary tumor, and few metastatic lesions, TKI monotherapy remains the preferred option. In the future, prognostic and treatment-response prediction models based on molecular stratification, including angiogenesis-related and immune pathways, may represent an important direction for achieving more precise individualized treatment.

Exploring Combination Regimens: Triplet Therapy and the Efficacy Limitations of First-Line Treatment

To further improve outcomes for patients with intermediate- and high-risk RCC, clinical studies have explored intensified triplet combination regimens. The COSMIC-313 study is a representative effort in this field. It evaluated cabozantinib combined with nivolumab and ipilimumab (targeted therapy plus dual immunotherapy) versus placebo plus dual immunotherapy as first-line treatment for patients with intermediate- or high-risk advanced/progressive renal cell carcinoma (aRCC), according to IMDC criteria.

The latest follow-up data showed that, at a median follow-up of 45 months, median PFS was 16.6 months in the triplet combination group and 11.2 months in the dual-immunotherapy group (P = 0.027). The HR for PFS reported in the final analysis was 0.82. Median OS was 41.9 months and 42.0 months, respectively (HR = 1.02, P = 0.84), with no statistically significant difference between the groups. These findings suggest that, in advanced renal cell carcinoma, simply adding more agents to a regimen does not necessarily translate into an overall survival benefit. Clinicians must also remain alert to increased toxicity and diminishing marginal benefits associated with treatment intensification. The ultimate value of triplet strategies combining dual targeted therapy and immunotherapy will need to be determined in light of the results of subsequent Phase III clinical studies.

Breakthroughs in Second-Line Treatment: FRUSICA-2 Establishes a New Benchmark for Targeted Therapy–Immunotherapy Combinations

After failure of first-line treatment, particularly TKI monotherapy, second-line treatment options were once quite limited. According to the CSCO guidelines, traditional second-line regimens, such as axitinib, everolimus, and nivolumab, have objective response rates (ORRs) of only 8.3%–25% and median progression-free survival (PFS) of 4.6–10 months, highlighting the substantial limitations in overall clinical benefit.

Against this background, the FRUSICA-2 study has provided new randomized controlled trial evidence to inform clinical practice. The study aimed to evaluate the efficacy and safety of fruquintinib plus sintilimab compared with axitinib or everolimus monotherapy in patients with locally advanced or metastatic renal cell carcinoma (RCC) whose disease had progressed following previous vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) treatment and who had not received prior PD-1/PD-L1 inhibitor therapy. According to assessment by the blinded independent review committee (BIRC), median PFS was 22.21 months in the combination group versus 6.90 months in the control group, corresponding to a hazard ratio (HR) of 0.373, with a statistically significant difference (P < 0.0001). The combination group also achieved an ORR of 60.5% and a median duration of response (DoR) of 23.69 months. These findings further support the therapeutic potential of this combination in the target population and provide an important reference for optimizing subsequent treatment strategies.

Exploratory subgroup analyses showed that fruquintinib plus sintilimab achieved better PFS and ORR than axitinib/everolimus across patients with different risk classifications, PD-L1 expression levels, and tumor burdens. In most prespecified subgroups, the trends in PFS and ORR benefit were consistent with those observed in the overall population. However, confidence intervals were wider in subgroups with smaller sample sizes, and these findings should therefore be interpreted cautiously. A single-agent factorial analysis showed that fruquintinib monotherapy achieved an ORR of 35.5% and a median PFS of 11.07 months. Cross-trial comparisons are affected by differences in enrolled populations, lines of treatment, and assessment methods; therefore, these results cannot be used to directly conclude that this regimen is superior to other first- or second-line treatment options.

Challenges After Immunotherapy: Diverse Subsequent-Line Strategies and Real-World Evidence

For patients whose disease progresses after combination immunotherapy, there is currently no single optimal subsequent-line regimen suitable for all patient populations. The CSCO guidelines recommend prioritizing clinical trial enrollment. Recent investigations have primarily focused on several approaches: HIF-2α (hypoxia-inducible factor 2 alpha) inhibitor monotherapy; combinations targeting multiple pathways, such as TKI plus TKI plus an mTOR inhibitor (mTORi), or TKI plus an HIF-2α inhibitor; and targeted therapy–immunotherapy combinations. Some of these studies have already reported encouraging efficacy.

In real-world studies, the HIF-2α inhibitor belzutifan has demonstrated favorable survival outcomes, with median OS reaching 21.0 months in patients with advanced RCC whose disease had progressed after IO/TKI treatment. The Phase III LITESPARK-011 study showed that lenvatinib plus belzutifan significantly prolonged PFS compared with cabozantinib in the second- or third-line setting after IO failure (14.8 months vs. 10.7 months; HR = 0.7), with an ORR of 52.6%.

In addition, a domestic Chinese Phase II single-arm study has provided further supporting evidence. Fruquintinib plus everolimus in patients with ccRCC whose disease had progressed after targeted therapy–immunotherapy combination treatment achieved a preliminary ORR as high as 66.7% and a median PFS of 10.0 months. Regarding safety, most treatment-related adverse events (TRAEs) were Grade 1–2, indicating favorable tolerability. These investigations provide additional evidence-based options for clinical practice after resistance to immunotherapy develops.

Surgical Practice: Perioperative Multidisciplinary Management of Renal Cancer with Inferior Vena Cava Tumor Thrombus

In the surgical treatment of advanced renal cancer, managing inferior vena cava (IVC) tumor thrombus is associated with high risks and considerable technical complexity. According to the Mayo classification system, surgical complexity and the risk of perioperative complications increase substantially with higher tumor thrombus levels, particularly for Level III and Level IV thrombi. The Department of Urology at The First Affiliated Hospital of Anhui Medical University has accumulated clinical experience in this area. A retrospective analysis of 73 patients who underwent tumor thrombus surgery between 2017 and 2026 showed a gradual increase in the clinical use of robot-assisted thrombectomy. Meanwhile, within a multidisciplinary team (MDT) framework, the team has explored neoadjuvant targeted therapy–immunotherapy in selected patients with high-level tumor thrombi. In individual cases, tumor thrombus shortening or a decrease in Mayo classification was observed, creating more favorable conditions for successful surgery. However, conclusions drawn from these single-center retrospective data still require further validation in prospective studies.

Surgical treatment of RCC with IVC tumor thrombus carries substantial risks, and surgery alone continues to face the dual challenges of local recurrence and distant metastasis. Tumor thrombus level, IMDC risk classification, pathological risk factors, and the patient’s overall condition are important considerations when developing neoadjuvant or adjuvant treatment strategies. For these complex cases, multidisciplinary collaborative decision-making should be maintained, alongside continuous monitoring for tumor recurrence and adverse events associated with systemic treatment, in order to maximize the potential for long-term survival benefit.

Concluding Remarks

The systemic treatment landscape for advanced renal cell carcinoma is undergoing profound changes. It has gradually evolved from a model centered primarily on monotherapy to one in which combination treatment plays a central role. At the same time, the focus of clinical decision-making has expanded beyond the pursuit of efficacy alone toward individualized management based on risk stratification. In this process, patient selection based on IMDC risk classification has become a key factor in determining first-line treatment strategies, while prospective second-line studies such as FRUSICA-2 are providing an increasingly robust evidence base for subsequent-line treatment decisions. In addition, for patients with complex renal cancer accompanied by IVC tumor thrombus, optimization of perioperative treatment pathways and deeper multidisciplinary collaboration are continuing to improve the precision of clinical management.

Overall, current clinical practice increasingly emphasizes the dynamic alignment of treatment evidence, patient characteristics, and predefined therapeutic goals. Looking ahead, further progress will depend on long-term follow-up data from mature randomized controlled trials, observations from real-world studies, and sustained collaboration among multidisciplinary teams in individualized decision-making. These efforts will help clarify the appropriate settings for next-generation targeted agents and comprehensive perioperative strategies, ultimately advancing the treatment of advanced renal cancer toward a more precise and systematic approach.

Professor Shuiping Yin